These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 32772807)
1. Multiple sclerosis management during the COVID-19 pandemic. Moss BP; Mahajan KR; Bermel RA; Hellisz K; Hua LH; Hudec T; Husak S; McGinley MP; Ontaneda D; Wang Z; Weber M; Tagliani P; Cárdenas-Robledo S; Zabalza A; Arrambide G; Carbonell-Mirabent P; Rodríguez-Barranco M; Sastre-Garriga J; Tintore M; Montalban X; Douglas M; Ogbuokiri E; Aravidis B; Cohen JA; Mowry EM; Fitzgerald KC Mult Scler; 2020 Sep; 26(10):1163-1171. PubMed ID: 32772807 [TBL] [Abstract][Full Text] [Related]
2. Keeping standards of multiple sclerosis care through the COVID-19 pandemic. Sastre-Garriga J; Tintoré M; Montalban X Mult Scler; 2020 Sep; 26(10):1153-1156. PubMed ID: 32552382 [No Abstract] [Full Text] [Related]
3. Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era. Ciotti JR; Grebenciucova E; Moss BP; Newsome SD Ann Neurol; 2020 Dec; 88(6):1062-1064. PubMed ID: 32951235 [No Abstract] [Full Text] [Related]
4. Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis. Landi D; Ponzano M; Nicoletti CG; Cecchi G; Cola G; Mataluni G; Mercuri NB; Sormani MP; Marfia GA Mult Scler Relat Disord; 2020 Oct; 45():102359. PubMed ID: 32663793 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 will change MS care forever - Yes. Meca-Lallana V Mult Scler; 2020 Sep; 26(10):1147-1148. PubMed ID: 32567486 [No Abstract] [Full Text] [Related]
6. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Safavi F; Nourbakhsh B; Azimi AR Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086 [TBL] [Abstract][Full Text] [Related]
8. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290 [TBL] [Abstract][Full Text] [Related]
9. Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic. Alnajashi H; Jabbad R PLoS One; 2020; 15(10):e0241103. PubMed ID: 33091088 [TBL] [Abstract][Full Text] [Related]
10. The COVID-19 pandemic and the use of MS disease-modifying therapies. Giovannoni G; Hawkes C; Lechner-Scott J; Levy M; Waubant E; Gold J Mult Scler Relat Disord; 2020 Apr; 39():102073. PubMed ID: 32334820 [No Abstract] [Full Text] [Related]
11. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices. Mateen FJ; Rezaei S; Alakel N; Gazdag B; Kumar AR; Vogel A J Neurol; 2020 Dec; 267(12):3467-3475. PubMed ID: 32638107 [TBL] [Abstract][Full Text] [Related]
12. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile. Ciampi E; Uribe-San-Martin R; Cárcamo C Mult Scler Relat Disord; 2020 Jul; 42():102204. PubMed ID: 32570203 [No Abstract] [Full Text] [Related]
13. Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study. Reed S; Gonzalez JM; Johnson FR Value Health; 2020 Nov; 23(11):1438-1443. PubMed ID: 33127014 [TBL] [Abstract][Full Text] [Related]
14. How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey. Morrison EH; Michtich K; Hersh CM Mult Scler Relat Disord; 2021 Jun; 51():102913. PubMed ID: 33839482 [TBL] [Abstract][Full Text] [Related]
15. Challenges in the Practice of Sexual Medicine in the Time of COVID-19 in the United Kingdom. Jacob L; Smith L; Butler L; Barnett Y; Grabovac I; McDermott D; Armstrong N; Yakkundi A; Tully MA J Sex Med; 2020 Jul; 17(7):1229-1236. PubMed ID: 32411271 [TBL] [Abstract][Full Text] [Related]
16. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745 [TBL] [Abstract][Full Text] [Related]
17. Importance of collecting data on socioeconomic determinants from the early stage of the COVID-19 outbreak onwards. Khalatbari-Soltani S; Cumming RC; Delpierre C; Kelly-Irving M J Epidemiol Community Health; 2020 Aug; 74(8):620-623. PubMed ID: 32385126 [TBL] [Abstract][Full Text] [Related]
18. Health Disparities and the Coronavirus Disease 2019 (COVID-19) Pandemic in the USA. Khatana SAM; Groeneveld PW J Gen Intern Med; 2020 Aug; 35(8):2431-2432. PubMed ID: 32462564 [No Abstract] [Full Text] [Related]
19. Rehabilitation Recommendations for Multiple Sclerosis Patients during the COVID-19 Pandemic. Naser Moghadasi A; Azadvari M; Sahraian MA Arch Iran Med; 2020 Jul; 23(7):509-510. PubMed ID: 32657605 [No Abstract] [Full Text] [Related]
20. Association of a Public Health Campaign About Coronavirus Disease 2019 Promoted by News Media and a Social Influencer With Self-reported Personal Hygiene and Physical Distancing in the Netherlands. Yousuf H; Corbin J; Sweep G; Hofstra M; Scherder E; van Gorp E; Zwetsloot PP; Zhao J; van Rossum B; Jiang T; Lindemans JW; Narula J; Hofstra L JAMA Netw Open; 2020 Jul; 3(7):e2014323. PubMed ID: 32639569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]